---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-005811"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:32:20.780896+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics appoints Patrick Fabbio as CFO effective Jan 30, 2023

## Summary
- Patrick Fabbio appointed CFO, replacing interim CFO Jesse Shefferman (CEO).
- Fabbio brings 30+ years life science finance experience; most recently President & CFO of Rafael Holdings.
- Compensation: $445k base salary, 45% target bonus, $25k signing bonus, 300k stock option (4-yr vest).
- Severance: without cause/good reason → 9 months base + 12 months target bonus + 9 months healthcare.
- On change-in-control termination within 12 months: 100% equity acceleration, 12 months base salary.

## SEC filing metadata
- accession: 0001213900-23-005811
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/ea172250-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-005811
- JSON: https://secwatch.observer/filing/0001213900-23-005811.json
- Plain text: https://secwatch.observer/filing/0001213900-23-005811.txt

## Key facts
- Executive change
  Patrick Fabbio was appointed as Chief Financial Officer at Protara Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 30, 2023, Protara Therapeutics, Inc. (the “Company”) announced that, effective as of January 30, 2023, Patrick Fabbio had been appointed as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm
- Executive change
  Jesse Shefferman changed role as Chief Financial Officer at Protara Therapeutics, Inc..
  - Action: replaced
  - Role: Chief Financial Officer
  source text: Mr. Fabbio will serve as the Company’s principal financial officer effective January 30, 2023, replacing Jesse Shefferman, the Company’s President and Chief Executive Officer, who had been serving in such role while the Company searched for a Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.